Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
Duality of statin action on lipoprotein subpopulations in the mixed dyslipidemia of metabolic syndrome: Quantity vs quality over time and implication of CETP.
|
29574070 |
2019 |
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
CKD-519, a potent cholesteryl ester transfer protein (CETP) inhibitor, is a clinical candidate being developed for the treatment of dyslipidemia.
|
30107219 |
2018 |
Dyslipidemias
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Conversely, Golden Syrian hamsters have a lipoprotein metabolism mimicking human dyslipidemia since it does express the cholesteryl ester transfer protein (CETP).
|
29155143 |
2018 |
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
Anacetrapib is a cholesteryl ester transfer protein (CETP) inhibitor being developed for the treatment of mixed dyslipidemia.
|
28884824 |
2018 |
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Dietary fat intake and genetic factors including CETP Taq1B polymorphism could also affect lipid profile concentrations, in particular HDL-c. We decided to study the frequency of this polymorphism and its interaction with dietary fat intake on HDL-c concentration among Iranian T2DM patients with and without dyslipidemia.
|
28065481 |
2018 |
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
Anacetrapib is a cholesteryl ester transfer protein inhibitor intended for the treatment of dyslipidemia.
|
30029292 |
2018 |
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
We aimed to assess the effects of cholesteryl ester transfer protein inhibitor anacetrapib added to statin ± other lipid-modifying therapies (LMT) in Japanese patients with dyslipidemia who were not at their LDL-C goal.
|
28478132 |
2017 |
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
In this review, we focus on dyslipidemia drug targets traceable to human genetic studies, including statins and ezetimibe, as well as promising new classes such as inhibitors of proprotein convertase subtilisin kexin 9, apolipoprotein B, microsomal triglyceride transfer protein, cholesteryl ester transfer protein, angiopoietin-like proteins types 3 and 4 and apolipoprotein C-III.
|
28109622 |
2017 |
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
Cholesteryl ester transfer protein (CETP) inhibitors are a new class of therapeutics for dyslipidemia that simultaneously improve two major cardiovascular disease (CVD) risk factors: elevated low-density lipoprotein (LDL) cholesterol and decreased high-density lipoprotein (HDL) cholesterol.
|
28911944 |
2017 |
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
Anacetrapib is a potent and selective CETP inhibitor and is undergoing phase III clinical trials for the treatment of dyslipidemia.
|
27432781 |
2017 |
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
Evacetrapib: Another CETP Inhibitor for Dyslipidemia With No Clinical Benefit.
|
28099220 |
2017 |
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
Additional safety evaluation (no blood pressure elevation in guinea pigs) and pharmacokinetics studies indicated that the potential druggability for compound 20 which is a promising lead for development of a new class of CETP inhibitors for the treatment of dyslipidemia.
|
28802120 |
2017 |
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The polymorphism of CETP genes rs708272, rs3764261, rs1800775, rs711752, rs12149545 was closely related to the dyslipidemia in the Xinjiang Uyghur and Kazakh ethnic groups; and the rs708272 T, rs3764261 T, rs711752 A, and rs12149545 A alleles could reduce risk of dyslipidemia in the Uyghur and Kazakh populations, however, the rs1800775 C allele showed risk factors.
|
26694435 |
2015 |
Dyslipidemias
|
0.400 |
PosttranslationalModification
|
group |
BEFREE |
CETP and LPL DNA methylation levels are associated with blood lipid profile, suggesting that further studies of epipolymorphisms should most certainly contribute to a better understanding of the molecular bases of dyslipidemia.
|
23623643 |
2013 |
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
Inhibition of CETP may reduce the risk of atherosclerosis in patients with dyslipidemia.
|
21122682 |
2011 |
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
Inhibition of CETP is considered a potential approach to treat dyslipidemia.
|
20556633 |
2010 |
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
Bexarotene induces dyslipidemia by increased very low-density lipoprotein production and cholesteryl ester transfer protein-mediated reduction of high-density lipoprotein.
|
19147676 |
2009 |
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
LHGDN |
CETP TaqIB polymorphism in Turkish adults: association with dyslipidemia and metabolic syndrome.
|
18849221 |
2008 |
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The contribution to dyslipidemia of 20 selected single nucleotide polymorphisms of 13 genes reported in the literature to be associated with plasma lipid levels (ABCA1, ADRB2, APOA5, APOC3, APOE, CETP, LIPC, LIPG, LPL, MDR1, MTP, SCARB1, and TNF) was assessed by longitudinally modeling more than 4400 plasma lipid determinations in 438 antiretroviral therapy-treated participants during a median period of 4.8 years.
|
17700364 |
2007 |
Dyslipidemias
|
0.400 |
Biomarker
|
group |
CTD_human |
Common single-nucleotide polymorphisms act in concert to affect plasma levels of high-density lipoprotein cholesterol.
|
17952847 |
2007 |
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
This article reviews the physiology of CETP in lipoprotein metabolism and the data in animals and humans that are relevant to the question of whether CETP inhibition may some day be part of the clinical armamentarium for treating dyslipidemia and atherosclerotic vascular disease.
|
15296707 |
2004 |
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
Single nucleotide polymorphisms (SNPs) and haplotypes in the CETP gene were determined in 98 patients with untreated dyslipidemias and analyzed for associations with plasma CETP and plasma lipids before and during statin treatment.
|
14583798 |
2003 |
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
CETP is often involved in secondary dyslipidemia and is susceptible to modify the composition of plasma lipoproteins in an atherogenic way.
|
8964591 |
1996 |